University of Iowa Research Foundation

The United States Government As Represented by the Department of Veterans Affairs

Jinhua Xiang

Jack T Stapleton

James H McLinden

Donna Klinzman

Nirjal Bhattarai

Qing Chang

Sarah George

Sabina Wünschmann

Warren Schmidt

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.

Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.

GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent

Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.

Flavivirus NS5A proteins for the treatment of HIV

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.

The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.

GB virus C and methods of treating viral infections

GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.

Growing community of inventors

Iowa City, IA, United States of America

Jinhua Xiang